# US 8,465,752 B2 · Treatment of renal hypertension or carotid sinus syndrome with adventitial pharmaceutical sympathetic denervation or neuromodulation > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,465,752 B2 - Document ID: US8465752B2 - Status: Granted - Kind: B2 - Application number: 12/765,720 - Filed: 2010-04-22 - Published: 2011-05-05 - Granted: 2013-06-18 - Earliest claimed: 2009-04-22 - Assignees: Mercator MedSystems, Inc. - Applicants: Kirk Patrick Seward - Inventors: Kirk Patrick Seward - Web page: https://patentgrep.com/patent/US8465752B2 ## CPC - A61M 25/1002: {characterised by balloon shape (A61M25/1006, A61M25/1009 take precedence)} - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2) - A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61M 5/00: Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests (tube connectors, tube couplings, valves or branch units, specially adapted for medical use A61M39/00; containers specially adapted for medical or pharmaceutical purposes A61J1/00) - A61M 5/007: {for contrast media} - A61M 5/44: having means for cooling or heating the devices or media - A61M 25/00: Catheters; Hollow probes (dilators A61M29/00; {peritoneal catheters A61M1/285; tracheal tubes A61M16/04; for drainage A61M27/00; for uterus, vagina or rectum A61M31/00} ; for measuring or testing A61B; {materials for catheters A61L29/00}) - A61M 25/0084: {being one or more injection needles} - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 9/12: Antihypertensives - A61M 2025/009: {the needle having a bent tip, i.e. the needle distal tip is angled in relation to the longitudinal axis of the catheter} - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient. ## Claims ### Claim 1 A method for treating hypertension in a subject, said method comprising the delivery of an amount of a neuromodulating agent to the nerves surrounding a blood vessel in a subject, wherein the amount is effective to lower systemic blood pressure by a therapeutically beneficial amount, and wherein delivery comprises injecting said agent into tissue bound on the inside by the external elastic lamina of said blood vessel and bound on the outside by the outer extent of the adventitial and perivascular connective tissues that surround the blood vessel. ### Claim 2 (depends on 1) A method as in claim 1, wherein delivery includes a step of positioning a needle through the wall of a target blood vessel so that an aperture of the needle is positioned beyond an external elastic lamina (EEL) of the wall. ### Claim 3 (depends on 1) A method as in claim 1, wherein delivery further includes a step of confirming that said neuromodulating agent is penetrating said tissue by imaging either the neuromodulating agent mixed with a diagnostic agent or by the delivery of a diagnostic agent prior to the delivery of the neuromodulating agent. ### Claim 4 (depends on 1) A method as in claim 1, wherein the blood vessel is an artery. ### Claim 5 (depends on 4) A method as in claim 4, wherein the artery is a renal artery. ### Claim 6 (depends on 1) A method as in claim 1, wherein the blood vessel is a vein. ### Claim 7 (depends on 6) A method as in claim 6, wherein the vein is a renal vein. ### Claim 8 (depends on 1) A method as in claim 1, wherein the neuromodulating agent is a neurotoxin or neurotoxin fragment. ### Claim 9 (depends on 8) A method as in claim 8, wherein the neurotoxin is a botulinum neurotoxin or fragment thereof. ### Claim 10 (depends on 9) A method as in claim 9, wherein the amount is between 10 picograms and 25 nanograms of active botulinum neurotoxin. ### Claim 11 (depends on 9) A method as in claim 9, wherein the amount is between 50 picograms and 10 nanograms of active botulinum neurotoxin. ### Claim 12 (depends on 9) A method as in claim 9, wherein the amount is between 100 picograms and 2.5 nanograms of active botulinum neurotoxin.